Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05280782 · ClinicalTrials.gov registry record · Early Phase 1
Development and Translation of Generator-Produced PET Tracer for Myocardial Perfusion Imaging-Dosimetry Group
A Early Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT05280782 is a Early Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 8 participants.
The verdict
NCT05280782, a Early Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study is a single center, early phase 1 clinical imaging study designed to assess the dosimetry of 68Ga-Galmydar for PET/CT imaging.
Interventions
- DRUG Ga-68 Galmydar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-01-05 |
| Est. Completion | 2022-05-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05280782
The ClinicalTrials.gov registry entry for NCT05280782 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ga-68 Galmydar is the first listed.
NCT05280782 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05280782 about?
NCT05280782 is a clinical study titled "Development and Translation of Generator-Produced PET Tracer for Myocardial Perfusion Imaging-Dosimetry Group". This study is a single center, early phase 1 clinical imaging study designed to assess the dosimetry of 68Ga-Galmydar for PET/CT imaging.
What is the current status of trial NCT05280782?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2022-01-05. Estimated completion is 2022-05-01.
What interventions are being tested in trial NCT05280782?
The interventions under investigation include: Ga-68 Galmydar (DRUG).
Who is sponsoring clinical trial NCT05280782?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.